Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at gene expression in tissue from patients with acute lymphoblastic leukemia enrolled in clinical trial ECOG-2993.

Detailed Description
-----------------
OBJECTIVES: Identify genes involved in specific biologic processes or molecular functions that contribute to the mechanisms by which the BCR/ABL tyrosine kinase induces a leukemic phenotype using RNA banked from patients with BCR/ABL-positive acute lymphoblastic leukemia (ALL) enrolled on ECOG-2993. Compare patterns of mRNA expression of BCR/ABL fusion protein in patients with B-lineage ALL vs patients with ALL and no cytogenetic abnormalities enrolled on ECOG-2993. Determine both shared and differing expression patterns in patients with BCR/ABL-positive and cytogenetically negative ALL with respect to achievement of complete remission and duration of disease-free and overall survival. OUTLINE: This is a multicenter study. Total RNA is isolated from stored tissue samples and integrity is verified by reverse transcription-polymerase chain reaction (RT-PCR). cDNA libraries are created from total RNA and gene expression is analyzed via microarray analysis. Genes of interest are further analyzed by flow cytometry and RT-PCR. PROJECTED ACCRUAL: A total of 137 patients will be accrued for this study.

Official Title
-----------------
Genetic Risk Classes in Adult Acute Lymphocytic Leukemia

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: microarray analysis
* Genetic: reverse transcriptase-polymerase chain reaction
* Other: flow cytometry


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Confirmed diagnosis of acute lymphoblastic leukemia Tissue banked on protocol ECOG-2993 meeting the following criteria: Leukemic blast cell population immunophenotyped in detail (e.g., including CD25) in ECOG's Immunophenotyping Reference Laboratory Flow cytometric analysis of gated blast cells reveals association with the B-cell lineage Mononuclear cell fraction used for RNA isolation contains 75-99% blasts (median 85%) Negative for TEL/AML1, MLL/AF4, and E2A/PBX1 by qualitative reverse transcription-polymerase chain reaction (RT-PCR) No FLT3 gene mutations BCR/ABL-positive samples meeting the following criteria: Presence of t(9;22)(q34;q11) by standard cytogenetics Detection of either p190 BCR/ABL or p210 BCR/ABL transcripts by qualitative RT-PCR Patients with genetic risk factors must meet the following criterion: Only a normal diploid karyotype is present in ≥ 15 metaphases by standard cytogenetics PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: microarray analysis|nan|
|Genetic: reverse transcriptase-polymerase chain reaction|nan|
|Other: flow cytometry|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genes involved in specific biologic processes or molecular functions that contribute to the mechanisms by which the BCR/ABL tyrosine kinase induces a leukemic phenotype |  | 1 month | 
| Comparison of patterns of mRNA expression of BCR/ABL fusion protein in patients with B-lineage acute lymphoblastic leukemia (ALL) vs patients with ALL who lack cytogenetic abnormalities |  | 1 month | 
| Shared and differing expression patterns in patients with BCR/ABL-positive and cytogenetically negative ALL with respect to achievement of complete remission and duration of disease-free and overall survival |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adult acute lymphoblastic leukemia in remission